PDF(Pubmed)
Abstract：
Gentamicin is an aminoglycoside antibiotic with a rapid bactericidal effect on the treatment of many infections. However, its use at high concentrations for more than 7 days causes nephrotoxic side effects. This study investigated the potential of Resatorvid and alpha lipoic acid (ALA) in mitigating gentamicin-induced nephrotoxicity in rats, considering biochemical, histopathological, and molecular parameters. This study randomly distributed 34 Wistar albino rats into four groups: healthy control (n = 6), Gentamicin (80 mg/kg, n = 7), Gentamicin + Sham (%10 hydroalcoholic solution, n = 7), Gentamicin + Resatorvid (5 mg/kg, n = 7), and Gentamicin + ALA (100 mg/kg, n = 7). Resatorvid treatment led to a statistically significant decrease in urinary IL-18, KIM-1, and NGAL levels, whereas ALA treatment significantly reduced KIM-1 levels compared to the gentamicin-only group. Both Resatorvid and ALA showed partial reductions in urine creatinine levels. Moreover, treatments with Resatorvid and ALA resulted in statistically significant decreases in NRF-2, CAS-3, and NR4A2 expressions. However, only Resatorvid demonstrated a statistically significant decrease in NF-B expression. These findings highlight the potential of Resatorvid in ameliorating gentamicin-induced nephrotoxicity, thereby expanding the therapeutic utility of gentamicin and enhancing its efficacy against infections.
摘要：
庆大霉素是一种氨基糖苷类抗生素，对许多感染的治疗具有快速的杀菌作用。然而,它在高浓度下使用超过7天会导致肾毒性副作用。这项研究调查了Resatorvid和α硫辛酸（ALA）在减轻庆大霉素诱导的大鼠肾毒性中的潜力，考虑到生化，组织病理学,和分子参数。本研究将34只Wistar白化病大鼠随机分为四组：健康对照组（n=6），庆大霉素（80mg/kg，n=7),庆大霉素+Sham(%10水醇溶液,n=7),庆大霉素+瑞舒维(5毫克/千克，n=7),和庆大霉素+ALA(100毫克/千克，n=7)。重新治疗导致尿IL-18、KIM-1和NGAL水平有统计学意义的下降，而与仅庆大霉素组相比,ALA治疗显著降低KIM-1水平.Resatorvid和ALA均显示尿肌酐水平部分降低。此外，用Resatorvid和ALA治疗导致NRF-2，CAS-3和NR4A2表达的统计学显着降低。然而,只有Resatorvid显示NF-B表达的统计学显着降低。这些发现强调了Resatorvid在改善庆大霉素诱导的肾毒性方面的潜力，从而扩大庆大霉素的治疗效用并增强其抗感染的功效。
